Featured in Nikkei: NBHL–FRONTEO AI Antibody Alliance
We are pleased to share that Nikkei Online has featured the collaboration between NB Health Laboratory (NBHL) and FRONTEO.
The article highlights our recently announced joint Proof-of-Concept (PoC) research agreement, which combines FRONTEO’s AI-driven drug discovery platform, Drug Discovery AI Factory (DDAIF), with NBHL’s proprietary GPCR-targeted antibody generation platform, MoGRAA. This partnership aims to accelerate the creation of innovative antibody drug pipelines targeting GPCRs, an area long regarded as one of the most challenging frontiers in drug discovery.
The coverage underscores the growing attention our groundbreaking drug discovery initiative is receiving within the healthcare and biopharmaceutical sectors. Moving forward, NBHL and FRONTEO remain committed to leveraging the synergy of AI and antibody discovery technologies to address unmet medical needs and deliver transformative therapies that improve patients’ quality of life.